A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
Latest Information Update: 30 Mar 2026
At a glance
- Drugs Retatrutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Hudson Biotech
Most Recent Events
- 30 Mar 2026 New trial record